Artificial intelligence (AI) and "protein language" models can speed the design of monoclonal antibodies that prevent or ...

Artificial intelligence (AI) and "protein language" models can speed the design of monoclonal antibodies that prevent or ...

Researchers showed that a protein language model could design functional human antibodies that recognized unique antigen ...

The TL1a inhibitor duvakitug was effective at 14 weeks in patients who had previous exposure to conventional and advanced ...

ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” “Company”), a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases, including ...

Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, and Mabqi, a biotechnology company focused on the discovery and development of fully human antibodies, announced ...

An announcement from Invivyd ( ($IVVD) ) is now available. On November 6, 2025, Invivyd reported its third-quarter financial results, highlighting ...

Coinciding with The Asset’s 25th anniversary, the highly regarded “The Asset ESG Corporate Awards” was renamed “The Asset Corporate Sustainability Leadership Awards” this year, underscoring the ...

A webcast of the presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will ...

Astria Therapeutics, Inc. , a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive results from the full enrollment ...

As drug development enters a new era, Certara is expanding its global team of scientists and technologists to lead the shift toward AI-powered testing methods.

In the phase 2 EDGE-Gastric trial (NCT05329766), the combination of monoclonal antibodies domvanalimab and zimberelimab ...